All In Biotech

Drug Trial Radar · NCT06868290

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Mar 13, 2025

Primary completion

Jun 7, 2029

Study completion May 24, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Conditions

  • ANCA Associated Vasculitis (AAV)

Interventions

  • Rapcabtagene autoleucelBiological

    Single infusion of rapcabtagene autoleucel

  • Active ComparatorOther

    Active comparator option as per protocol

  • GlucocorticoidsDrug

    Concomitant glucocorticoids as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: From randomization until the occurrence of an EFS event, up to approx. 4 years after randomization

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • University Of Colorado

    Aurora, Colorado

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Northwestern University

    Chicago, Illinois

  • Uni of Chi Medi Ctr Hema and Onco

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Michigan Med University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Duke Clinical Research Institute

    Durham, North Carolina

  • Oregon Health Sciences University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Baylor University Medical Center

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • LDS Hospital

    Salt Lake City, Utah

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Haifa, Israel

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Fukuoka, Japan

  • Novartis Investigative Site

    Ishikawa, Japan

  • Novartis Investigative Site

    Kyoto, Japan

  • Novartis Investigative Site

    Chiba, Chiba, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, Japan

  • Novartis Investigative Site

    Suita, Osaka, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site

    Riyadh, Saudi Arabia

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore, Singapore

  • Novartis Investigative Site

    Basel, Switzerland

  • Novartis Investigative Site

    Bern, Switzerland

  • Novartis Investigative Site

    Cambridge, United Kingdom

  • Novartis Investigative Site

    Glasgow, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.